Artivion (NYSE:AORT) Receives Buy Rating from Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of Artivion (NYSE:AORT) in a report issued on Friday, Benzinga reports. Needham & Company LLC currently has a $30.00 target price on the stock.

A number of other brokerages also recently weighed in on AORT. Stifel Nicolaus upped their price target on shares of Artivion from $25.00 to $28.00 and gave the company a buy rating in a report on Friday. Lake Street Capital lifted their price target on shares of Artivion from $28.00 to $30.00 and gave the stock a buy rating in a research report on Tuesday, July 2nd. Finally, Oppenheimer upped their price target on Artivion from $25.00 to $30.00 and gave the company an outperform rating in a report on Friday.

Artivion Price Performance

Shares of AORT traded down $0.48 during midday trading on Friday, reaching $24.85. The stock had a trading volume of 333,796 shares, compared to its average volume of 227,044. The firm’s 50 day moving average price is $25.36 and its 200-day moving average price is $22.12. Artivion has a 52 week low of $12.16 and a 52 week high of $29.24. The company has a market capitalization of $1.04 billion, a P/E ratio of -103.54 and a beta of 1.75. The company has a debt-to-equity ratio of 1.07, a current ratio of 6.04 and a quick ratio of 4.26.

Institutional Trading of Artivion

Institutional investors have recently made changes to their positions in the stock. SG Americas Securities LLC lifted its position in Artivion by 7.8% in the 4th quarter. SG Americas Securities LLC now owns 13,393 shares of the company’s stock worth $239,000 after buying an additional 968 shares in the last quarter. Louisiana State Employees Retirement System acquired a new position in Artivion in the 4th quarter worth about $349,000. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Artivion by 25.3% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,430 shares of the company’s stock worth $186,000 after purchasing an additional 2,108 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Artivion by 2.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 326,085 shares of the company’s stock worth $5,830,000 after purchasing an additional 8,090 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in shares of Artivion by 5.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,686,502 shares of the company’s stock valued at $30,156,000 after buying an additional 80,214 shares in the last quarter. 86.37% of the stock is currently owned by institutional investors and hedge funds.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.